PHARMAKON ADVISORS, LP
PHARMAKON ADVISORS, LP is a Series C+ fund in the US and Western Europe writing $100M–$500M checks into biotechnology, pharmaceuticals, medical-technology and diagnostics.
- Stages
- Series C+
- Sectors
- biotechnology, pharmaceuticals, medical-technology, diagnostics
- Check size
- $100M–$500M
- Invests in
- US-wide, Western Europe
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2009
- Assets under management
- $3.05B
- Website
- pharmakonadvisors.com
Thesis
Pharmakon Advisors, LP is a life sciences debt specialist founded in 2009, providing non-dilutive debt financing solutions. Their strategy focuses on acquiring high-yield debt securities and instruments like senior secured debt and capped return royalties, securitized by life sciences company assets and royalty payments. They target companies with strong sales visibility, from emerging growth to commercial-stage entities, primarily in North America and Western Europe. As of December 31, 2025, their AUM was approximately $3.05 billion, with a total commitment of over $13 billion across 78 transactions since inception. They have raised $5.3 billion across five private funds and a publicly traded UK trust, BioPharma Credit PLC. While specific check sizes aren't detailed, they have participated in significant debt rounds, including a $100 million financing for Paratek Pharmaceuticals and Radius Health, a $500 million facility with Mineralys Therapeutics, and a CHF 250 million term loan with Idorsia, indicating substantial investment capacity. Their headquarters are in New York, NY.
Common questions
Does PHARMAKON ADVISORS, LP invest at the Series C+ stage?
Yes. PHARMAKON ADVISORS, LP lists Series C+ among the stages it invests in.
What check size does PHARMAKON ADVISORS, LP write?
PHARMAKON ADVISORS, LP writes $100M–$500M checks.
Where does PHARMAKON ADVISORS, LP invest?
PHARMAKON ADVISORS, LP invests in the US and Western Europe.